- Home
- CKPT vs OPRT Comparison
CKPT vs OPRT Comparison
Compare CKPT & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- OPRT
- Stock Information
- Founded
- CKPT 2014
- OPRT 2005
- Country
- CKPT United States
- OPRT United States
- Employees
- CKPT N/A
- OPRT N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- OPRT Finance: Consumer Services
- Sector
- CKPT Health Care
- OPRT Finance
- Exchange
- CKPT Nasdaq
- OPRT Nasdaq
- Market Cap
- CKPT 172.4M
- OPRT 146.4M
- IPO Year
- CKPT 2017
- OPRT 2019
- Fundamental
- Price
- CKPT $3.13
- OPRT $7.89
- Analyst Decision
- CKPT Strong Buy
- OPRT Buy
- Analyst Count
- CKPT 3
- OPRT 4
- Target Price
- CKPT $12.00
- OPRT $5.17
- AVG Volume (30 Days)
- CKPT 753.4K
- OPRT 810.8K
- Earning Date
- CKPT 03-21-2025
- OPRT 02-12-2025
- Dividend Yield
- CKPT N/A
- OPRT N/A
- EPS Growth
- CKPT N/A
- OPRT N/A
- EPS
- CKPT N/A
- OPRT N/A
- Revenue
- CKPT $47,000.00
- OPRT $763,600,000.00
- Revenue This Year
- CKPT N/A
- OPRT N/A
- Revenue Next Year
- CKPT $300,658.78
- OPRT $8.34
- P/E Ratio
- CKPT N/A
- OPRT N/A
- Revenue Growth
- CKPT N/A
- OPRT N/A
- 52 Week Low
- CKPT $1.38
- OPRT $2.05
- 52 Week High
- CKPT $4.50
- OPRT $9.25
- Technical
- Relative Strength Index (RSI)
- CKPT 46.36
- OPRT 77.71
- Support Level
- CKPT $3.10
- OPRT $5.43
- Resistance Level
- CKPT $3.43
- OPRT $9.25
- Average True Range (ATR)
- CKPT 0.26
- OPRT 0.71
- MACD
- CKPT 0.00
- OPRT 0.27
- Stochastic Oscillator
- CKPT 33.03
- OPRT 72.59
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.